EUCTR2017-000327-27-Outside-EU/EEA进行中（未招募）1 期
An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Males and Females 2-15 years of age
- •-Genetic documentation of 5qSMA (homozygous gene deletion or mutation)
- •-Clinical signs attributable to SMA
- •-Able to complete all study procedures, measurements, and visits and parent/patient has adequately supportive psychological circumstances, in the opinion of the investigator
- •-Estimated life expectancy >2 years from Screening
- •-Meets age-appropriate institutional criteria for use of anesthesia/sedation, if use is planned for study procedure
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 34
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Respiratory insufficiency defined by the medical necessity for invasive or non-invasive ventilation during a 24-hour period
- •-Medical necessity for a gastric feeding tube, where the majority of feeds are given by this route, as assessed by the Investigator
- •-Previous scoliosis surgery that would interfere with the lumbar puncture injection procedure
- •-Hospitalization for surgery (e.g. scoliosis surgery) or pulmonary event within 2 months of screening or planned during the duration of the study
- •-Presence of an untreated or inadequately treated active infection requiring systemic antiviral or antimicrobial therapy at any time during the screening period
- •-History of brain or spinal cord disease that would interfere with lumbar puncture procedures or cerebrospinal fluid (CSF) circulation
- •-Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter
- •-History of bacterial meningitis
- •-Dosing with ISIS 396443 in clinical study ISIS 396443-CS1 Cohorts 2, 3, or 4
- •-Dosing with ISIS 396443 in clinical study ISIS 396443-CS10
- •-Clinically significant abnormalities in hematology or clinical chemistry parameters or ECG at the Screening visit, as assessed by the Site Investigator that would render the subject unsuitable for inclusion
- •-Treatment with investigational drug, biological agent, or device within 1-month of Screening or 5 half-lives of study agent, whichever is longer. Treatment with valproate or hydroxyurea within 3-months of screening. Any history of gene therapy or cell transplantation
- •-Ongoing medical condition that would interfere with the conduct and assessments of the study. Examples are medical disability (e.g. wasting or cachexia, sever anemia) that would interfere with the assessment of safety or would compromise the ability of the patient to undergo study procedures
研究者
相似试验
已完成
1 期
An interventional study to evaluate the safety, tolerability (how well a substance is tolerated by participants), and Pharmacokinetics (PK, the measure of how the human body processes a substance), of different dosages of TTI-0102 when given to healthy participants as either a single oral dose, or as an oral dose give twice daily on one day (as a potential treatment for COVID-19), compared with a single oral dose of the marketed product Cystagon (registered trademark).ACTRN12621000131853Thiogenesis Therapeutics, Inc.12
进行中（未招募）
1 期
Study to test a new drug to treat patients with Pulmonary Arterial Hypertension (PAH).Pulmonary arterial hypertensionEUCTR2017-000212-41-ESGlaxoSmithKline, S.A.24
进行中（未招募）
1 期
Study to test a new drug to treat patients with Pulmonary Arterial Hypertension (PAH)MedDRA version: 20.0Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10077739Term: Pulmonary arterial hypertension WHO functional class ISystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10077729Term: Pulmonary arterial hypertension WHO functional class IIISystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10077740Term: Pulmonary arterial hypertension WHO functional class IISystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersPulmonary arterial hypertensionEUCTR2017-000212-41-DEGlaxoSmithKline Research & Development Ltd23
进行中（未招募）
1 期
Phase 1/2 study of IMC-M113V in virologically suppressed chronic HIV infectioCTIS2024-513938-38-00Immunocore Limited30
进行中（未招募）
1 期
Phase 1/2 study of IMC-M113V in virologically suppressed chronic HIV infectioEUCTR2021-002008-11-ESImmunocore Limited53